Schleimhautmelanome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s00761-023-01377-y.pdf
Reference34 articles.
1. Eigentler et al (2020) S3 – Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms. https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14307_g. Zugegriffen: 18.06.2023
2. Ascierto PA, Del Vecchio M, Mandalá M et al (2020) Adjuvant nivolumab versus ipilimumab in resected stage IIIB‑C and stage IV melanoma (CheckMate 238): 4‑year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 21:1465–1477
3. Bai X, Mao LL, Chi ZH et al (2017) BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma 64:626–632
4. Beadling C, Jacobson-Dunlop E, Hodi FS et al (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14:6821–6828
5. Carvajal RD, Antonescu CR, Wolchok JD et al (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327–2334
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3